Expert assay development services for drug discovery.
Gyrasol is developing multiplexed arrays of signaling activity assays to explore the functional impact of oncogene mutations, for potential use in conjunction with targeted therapeutics to enable personalized medicine.
Company Overview
Gyrasol Technologies offers expert assay development services for drug discovery. We have discovered and developed novel sensors that enable simultaneous monitoring of protein kinase, lipid kinase, phosphatase, protease and phosphodiesterase activities in small biological samples. The platform provides assays that can be utilized throughout the drug development process.
In conjunction, Gyrasol is developing multiplexed arrays of signaling activity assays to explore the functional impact of oncogene mutations, for potential use in conjunction with targeted therapeutics to enable personalized medicine.
Gyrasol Technology
Gyrasol Technologies assays for protein kinases, lipid kinases, phosphatases and phosphodiesterases offer key advantages including a homogeneous direct detection platform formatted for HTS or for use in cellular lysates; requires no spectral overlap between donor and acceptor fluors; no radioactivity or costly antibodies are required; adaptable to physiological substrate and ATP concentrations using standard instrumentation.
Get in Touch
Contact Gyrasol to learn how our multiplexed arrays can help personalize cancer treatment. We look forward to hearing from you.